LeMaitre Vascular Inc (NASDAQ:LMAT) – Equities research analysts at First Analysis issued their Q4 2018 earnings per share (EPS) estimates for shares of LeMaitre Vascular in a research note issued to investors on Friday. First Analysis analyst anticipates that the medical instruments supplier will post earnings per share of $0.28 for the quarter. First Analysis also issued estimates for LeMaitre Vascular’s FY2019 earnings at $1.13 EPS.
LMAT has been the topic of a number of other reports. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Thursday, December 28th. BidaskClub cut shares of LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 27th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of “Hold” and a consensus price target of $34.00.
Shares of LeMaitre Vascular (NASDAQ:LMAT) traded down $0.31 during mid-day trading on Monday, hitting $36.78. 60,969 shares of the stock were exchanged, compared to its average volume of 123,785. The company has a market cap of $713.02, a PE ratio of 43.92, a price-to-earnings-growth ratio of 2.53 and a beta of 0.55. LeMaitre Vascular has a 12 month low of $22.16 and a 12 month high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The company had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $26.23 million. LeMaitre Vascular had a net margin of 17.03% and a return on equity of 16.93%. LeMaitre Vascular’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.13 EPS.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. boosted its position in shares of LeMaitre Vascular by 181.2% during the 3rd quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after acquiring an additional 2,667 shares in the last quarter. Royal Bank of Canada boosted its position in shares of LeMaitre Vascular by 856.5% during the 2nd quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 4,505 shares in the last quarter. Advisor Group Inc. boosted its position in shares of LeMaitre Vascular by 119.1% during the 3rd quarter. Advisor Group Inc. now owns 5,483 shares of the medical instruments supplier’s stock worth $205,000 after acquiring an additional 2,980 shares in the last quarter. Hartford Investment Management Co. acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $231,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $235,000. 72.88% of the stock is currently owned by institutional investors.
In other news, CEO George W. Lemaitre sold 42,036 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $35.68, for a total transaction of $1,499,844.48. Following the transaction, the chief executive officer now directly owns 3,259,263 shares of the company’s stock, valued at $116,290,503.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $34.55, for a total transaction of $518,250.00. Following the transaction, the chief executive officer now directly owns 3,225,709 shares in the company, valued at $111,448,245.95. The disclosure for this sale can be found here. Insiders have sold 137,736 shares of company stock worth $4,866,186 over the last ninety days. Insiders own 23.70% of the company’s stock.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Wednesday, March 21st. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.06. This represents a $0.28 annualized dividend and a dividend yield of 0.76%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 25.88%.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/13/lemaitre-vascular-inc-forecasted-to-earn-q4-2018-earnings-of-0-28-per-share-lmat.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.